The presence of a non-structural protein 1 (NS1) in tick-borne encephalitis (TBE) vaccines and the possible induction of an NS1-specific immune response in vaccinated individuals remains a somewhat controversial topic. Previously, we detected the presence of NS1 in the Encepur TBE vaccine by mass spectrometry and found the induction of NS1-specific IgG antibodies in mice vaccinated with the FSME-Immun TBE vaccine. Here, in this follow-up study, we examined the dynamics and extent of the NS1-specific IgG response in mice vaccinated with these two vaccines in more detail and compared it with the IgG response to the whole virus (WV). Mice were vaccinated at two-week intervals with a total of six doses of each vaccine, and levels of IgG antibodies to TBE virus WV and NS1 were measured by ELISA after each dose. Both vaccines elicited a robust anti-WV IgG response after two doses. The Encepur vaccine did not elicit NS1-specific IgG even after all six doses. In contrast, the FSME-Immun vaccine triggered the production of NS1-specific IgG after four doses. The results indicate that FSME-Immun is the only vaccine that elicits an NS1-specific antibody response in mice. However, compared to WV-specific IgG, the NS1-specific response is weaker, and a higher number of doses is required to induce detectable levels of NS1-specific IgG antibodies.

Department of Experimental Biology Faculty of Science Masaryk University Kamenice 735 5 CZ 62500 Brno Czech Republic

Laboratory of Arbovirology Institute of Parasitology Biology Centre of the Czech Academy of Sciences Branisovska 31 CZ 37005 Ceske Budejovice Czech Republic

Laboratory of Emerging Viral Infections Veterinary Research Institute Hudcova 70 CZ 62100 Brno Czech Republic

Zobrazit více v PubMed

Simmonds P., Becher P., Bukh J., Gould E.A., Meyers G., Monath T., Muerhoff S., Pletnev A., Rico-Hesse R., Smith D.B., et al. ICTV Virus Taxonomy Profile: Flaviviridae. J. Gen. Virol. 2017;98:2–3. doi: 10.1099/jgv.0.000672. PubMed DOI PMC

Ruzek D., Avšič Županc T., Borde J., Chrdle A., Eyer L., Karganova G., Kholodilov I., Knap N., Kozlovskaya L., Matveev A., et al. Tick-borne encephalitis in Europe and Russia: Review of pathogenesis, clinical features, therapy, and vaccines. Antivir. Res. 2019;164:23–51. doi: 10.1016/j.antiviral.2019.01.014. PubMed DOI

Fares W., Dachraoui K., Cherni S., Barhoumi W., Slimane T.B., Younsi H., Zhioua E. Tick-borne encephalitis virus in Ixodes ricinus (Acari: Ixodidae) ticks, Tunisia. Ticks Tick-Borne Dis. 2021;12:101606. doi: 10.1016/j.ttbdis.2020.101606. PubMed DOI

Kohlmaier B., Schweintzger N.A., Sagmeister M.G., Švendová V., Kohlfürst D.S., Sonnleitner A., Leitner M., Berghold A., Schmiedberger E., Fazekas F., et al. Clinical Characteristics of Patients with Tick-Borne Encephalitis (TBE): A European Multicentre Study from 2010 to 2017. Microorganisms. 2021;9:1420. doi: 10.3390/microorganisms9071420. PubMed DOI PMC

Ergunay K., Tkachev S., Kozlova I., Růžek D. A Review of Methods for Detecting Tick-Borne Encephalitis Virus Infection in Tick, Animal, and Human Specimens. Vector Borne Zoonotic Dis. 2016;16:4–12. doi: 10.1089/vbz.2015.1896. PubMed DOI

Taba P., Schmutzhard E., Forsberg P., Lutsar I., Ljøstad U., Mygland Å., Levchenko I., Strle F., Steiner I. EAN consensus review on prevention, diagnosis and management of tick-borne encephalitis. Eur. J. Neurol. 2017;24:1214-e61. doi: 10.1111/ene.13356. PubMed DOI

Albinsson B., Vene S., Rombo L., Blomberg J., Lundkvist Å., Rönnberg B. Distinction between serological responses following tick-borne encephalitis virus (TBEV) infection vs. vaccination, Sweden 2017. Eurosurveillance. 2018;23:17-00838. doi: 10.2807/1560-7917.ES.2018.23.3.17-00838. PubMed DOI PMC

Salat J., Mikulasek K., Larralde O., Pokorna Formanova P., Chrdle A., Haviernik J., Elsterova J., Teislerova D., Palus M., Eyer L., et al. Tick-Borne Encephalitis Virus Vaccines Contain Non-Structural Protein 1 Antigen and may Elicit NS1-Specific Antibody Responses in Vaccinated Individuals. Vaccines. 2020;8:81. doi: 10.3390/vaccines8010081. PubMed DOI PMC

Girl P., Bestehorn-Willmann M., Zange S., Borde J.P., Dobler G., von Buttlar H. Tick-Borne Encephalitis Virus Nonstructural Protein 1 IgG Enzyme-Linked Immunosorbent Assay for Differentiating Infection versus Vaccination Antibody Responses. J. Clin. Microbiol. 2020;58:e01783-19. doi: 10.1128/JCM.01783-19. PubMed DOI PMC

Mora-Cárdenas E., Aloise C., Faoro V., Knap Gašper N., Korva M., Caracciolo I., D’Agaro P., Avšič-Županc T., Marcello A. Comparative specificity and sensitivity of NS1-based serological assays for the detection of flavivirus immune response. PLoS Negl. Trop. Dis. 2020;14:e0008039. doi: 10.1371/journal.pntd.0008039. PubMed DOI PMC

Albinsson B., Rönnberg B., Vene S., Lundkvist Å. Antibody responses to tick-borne encephalitis virus non-structural protein 1 and whole virus antigen-a new tool in the assessment of suspected vaccine failure patients. Infect. Ecol. Epidemiol. 2019;9:1696132. doi: 10.1080/20008686.2019.1696132. PubMed DOI PMC

Stiasny K., Leitner A., Holzmann H., Heinz F.X. Dynamics and Extent of Non-Structural Protein 1-Antibody Responses in Tick-Borne Encephalitis Vaccination Breakthroughs and Unvaccinated Patients. Viruses. 2021;13:1007. doi: 10.3390/v13061007. PubMed DOI PMC

Beauté J., Spiteri G., Warns-Petit E., Zeller H. Tick-borne encephalitis in Europe, 2012 to 2016. Eurosurveillance. 2018;23:1800201. doi: 10.2807/1560-7917.ES.2018.23.45.1800201. PubMed DOI PMC

Kuzmenko Y.V., Starodubova E.S., Shevtsova A.S., Chernokhaeva L.L., Latanova A.A., Preobrazhenskaia O.V., Timofeev A.V., Karganova G.G., Karpov V.L. Intracellular degradation and localization of NS1 of tick-borne encephalitis virus affect its protective properties. J. Gen. Virol. 2017;98:50–55. doi: 10.1099/jgv.0.000700. PubMed DOI

Volpina O.M., Volkova T.D., Koroev D.O., Ivanov V.T., Ozherelkov S.V., Khoretonenko M.V., Vorovitch M.F., Stephenson J.R., Timofeev A.V. A synthetic peptide based on the NS1 non-structural protein of tick-borne encephalitis virus induces a protective immune response against fatal encephalitis in an experimental animal model. Virus Res. 2005;112:95–99. doi: 10.1016/j.virusres.2005.03.026. PubMed DOI

Aleshin S.E., Timofeev A.V., Khoretonenko M.V., Zakharova L.G., Pashvykina G.V., Stephenson J.R., Shneider A.M., Altstein A.D. Combined prime-boost vaccination against tick-borne encephalitis (TBE) using a recombinant vaccinia virus and a bacterial plasmid both expressing TBE virus non-structural NS1 protein. BMC Microbiol. 2005;5:45. doi: 10.1186/1471-2180-5-45. PubMed DOI PMC

Khoretonenko M.V., Vorovitch M.F., Zakharova L.G., Pashvykina G.V., Ovsyannikova N.V., Stephenson J.R., Timofeev A.V., Altstein A.D., Shneider A.M. Vaccinia virus recombinant expressing gene of tick-borne encephalitis virus non-structural NS1 protein elicits protective activity in mice. Immunol. Lett. 2003;90:161–163. doi: 10.1016/j.imlet.2003.09.002. PubMed DOI

Timofeev A.V., Butenko V.M., Stephenson J.R. Genetic vaccination of mice with plasmids encoding the NS1 non-structural protein from tick-borne encephalitis virus and dengue 2 virus. Virus Genes. 2004;28:85–97. doi: 10.1023/B:VIRU.0000012266.04871.ce. PubMed DOI

Jacobs S.C., Stephenson J.R., Wilkinson G.W. Protection elicited by a replication-defective adenovirus vector expressing the tick-borne encephalitis virus non-structural glycoprotein NS1. Pt 9J. Gen. Virol. 1994;75:2399–2402. doi: 10.1099/0022-1317-75-9-2399. PubMed DOI

Robbiani D.F., Růžek D. A dark side to NS1 antibodies? J. Exp. Med. 2021;218:e20211348. doi: 10.1084/jem.20211348. PubMed DOI PMC

Cavazzoni C.B., Bozza V.B.T., Lucas T.C.V., Conde L., Maia B., Mesin L., Schiepers A., Ersching J., Neris R.L.S., Conde J.N., et al. The immunodominant antibody response to Zika virus NS1 protein is characterized by cross-reactivity to self. J. Exp. Med. 2021;218:e20210580. doi: 10.1084/jem.20210580. PubMed DOI PMC